Amyloid peptide variant
IAPP peptides from specific animals inhibit hIAPP aggregation and provide cellular protection, addressing the inadequacies of current treatments for amyloid diseases by preventing disease progression.
JP2026094195APending Publication Date: 2026-06-09LOYOLA MARYMOUNT UNIV +1
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- LOYOLA MARYMOUNT UNIV
- Filing Date
- 2026-02-13
- Publication Date
- 2026-06-09
AI Technical Summary
Technical Problem
Existing treatments for amyloid diseases, such as type 2 diabetes, are inadequate in preventing or slowing the progression of the disease, and the role of misfolded proteins like human islet amyloid polypeptide (hIAPP) in disease progression remains unclear.
Method used
Development of IAPP peptides from animals like cats, dogs, chickens, polar bears, and seals that inhibit hIAPP aggregation and protect mammalian cells from toxicity, formulated into pharmaceutical compositions for administration.
Benefits of technology
The IAPP peptides effectively inhibit hIAPP aggregation and protect cells from toxicity, offering potential therapeutic benefits for amyloid diseases.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026094195000007 
Figure 2026094195000008 
Figure 2026094195000009
Abstract
This invention provides IAPP peptides that inhibit the aggregation of human pancreatic islet amyloid polypeptides and their use in inhibiting amyloid fibril formation. [Solution] We provide a series of IAPP peptides having a specific sequence that inhibit human IAPP aggregation and rescue mammalian cells from hIAPP toxicity. These IAPP variants are potent inhibitors of hIAPP aggregation and can be used as therapeutic agents and probes to understand the underlying toxicity of amyloid proteins.
Need to check novelty before this filing date? Find Prior Art